U.S. Markets open in 4 hrs 55 mins
  • S&P Futures

    3,833.00
    -1.00 (-0.03%)
     
  • Dow Futures

    30,927.00
    -9.00 (-0.03%)
     
  • Nasdaq Futures

    11,813.25
    +4.75 (+0.04%)
     
  • Russell 2000 Futures

    1,739.50
    -2.20 (-0.13%)
     
  • Crude Oil

    100.73
    +1.23 (+1.24%)
     
  • Gold

    1,769.20
    +5.30 (+0.30%)
     
  • Silver

    19.29
    +0.17 (+0.88%)
     
  • EUR/USD

    1.0263
    -0.0007 (-0.0718%)
     
  • 10-Yr Bond

    2.8090
    0.0000 (0.00%)
     
  • Vix

    27.53
    0.00 (0.00%)
     
  • GBP/USD

    1.1970
    +0.0018 (+0.1484%)
     
  • USD/JPY

    135.2280
    -0.6140 (-0.4520%)
     
  • BTC-USD

    20,203.89
    +220.40 (+1.10%)
     
  • CMC Crypto 200

    441.11
    +1.09 (+0.25%)
     
  • FTSE 100

    7,156.49
    +131.02 (+1.86%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced new efficacy data supporting the Phase 3 development of XEN1101.

  • XEN1101 rapidly reduced focal onset seizure frequency within one week for all doses compared with placebo.

  • At Week 1, the median percent reduction in monthly focal onset seizure frequency was 55.4% in the 25 mg group, 41.5% (20 mg), and 39.1% (10 mg) compared to 20.2% in the placebo group.

  • Based on the data, a key secondary endpoint in the Phase 3 trials will include the median percent change of weekly FOS at Week 1.

  • Related: Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment.

  • Seizure frequency continued to improve for the open-label extension (OLE) population during the first month after the 8-week double-blind period (DBP), suggesting that the efficacy signal can persist and may improve in the planned 12-week DBP of the XEN1101 Phase 3 trials.

  • Subjects remaining in the X-TOLE OLE for at least three months and 12 months experienced a greater than 70% and 80% reduction in median monthly seizure frequency compared to the DBP baseline.

  • 54 (19.6%) and 26 (9.5%) of subjects in the OLE experienced a ≥6 and a ≥12 consecutive months of seizure freedom, respectively.

  • Xenon also priced its underwritten public offering of 7.9 million shares and pre-funded warrants to purchase up to 327,868 shares at $30.50 per common share, with gross proceeds of $250 million.

  • Price Action: XENE shares are down 13.52% at $30.01 during the premarket session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.